GlycoMimetics (GLYC) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021
March 3, 2022 7:30 AM ESTPost year-end 2022 remains target for top-line data release of GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) National Cancer Institute (NCI) to conduct post-Phase 2 interim analysis based on event-free survival for the NCI-sponsored Phase 2/3 registration trial evaluating uproleselan in older, newly diagnosed AML patients fit for chemotherapy Apollomics Phase 3 uproleselan trial in Greater China initiated in November 2021 Investigational New Drug (IND) activities continued for GMI-1687 for treatment of acute vaso-occlusive crisis (VOC) of sickle cell disease; IND submission targeted for first half... More
